Antibe Therapeutics Stock Performance
| ATBPF Stock | USD 0.22 0.00 0.00% |
The firm shows a Beta (market volatility) of 0.0, which signifies not very significant fluctuations relative to the market. the returns on MARKET and Antibe Therapeutics are completely uncorrelated.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Antibe Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable basic indicators, Antibe Therapeutics is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 72 M | |
| Total Cashflows From Investing Activities | -20.2 M |
Antibe |
Antibe Therapeutics Relative Risk vs. Return Landscape
If you would invest 22.00 in Antibe Therapeutics on September 1, 2024 and sell it today you would earn a total of 0.00 from holding Antibe Therapeutics or generate 0.0% return on investment over 90 days. Antibe Therapeutics is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded pink sheets are less volatile than Antibe, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Antibe Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Antibe Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Antibe Therapeutics, and traders can use it to determine the average amount a Antibe Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| ATBPF |
Based on monthly moving average Antibe Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Antibe Therapeutics by adding Antibe Therapeutics to a well-diversified portfolio.
Antibe Therapeutics Fundamentals Growth
Antibe Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Antibe Therapeutics, and Antibe Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Antibe Pink Sheet performance.
| Return On Equity | -0.4 | |||
| Return On Asset | -0.16 | |||
| Current Valuation | (19.98 M) | |||
| Shares Outstanding | 52.14 M | |||
| Price To Earning | (1.67) X | |||
| Price To Book | 0.61 X | |||
| Price To Sales | 2.96 X | |||
| EBITDA | (25.14 M) | |||
| Cash And Equivalents | 50.19 M | |||
| Cash Per Share | 0.96 X | |||
| Total Debt | 205 K | |||
| Debt To Equity | 0 % | |||
| Book Value Per Share | 0.90 X | |||
| Cash Flow From Operations | (16.92 M) | |||
| Earnings Per Share | (0.41) X | |||
| Total Asset | 89.16 M | |||
| Retained Earnings | (12.08 M) | |||
| Current Asset | 3.96 M | |||
| Current Liabilities | 2.51 M | |||
About Antibe Therapeutics Performance
By analyzing Antibe Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Antibe Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Antibe Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Antibe Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. Antibe Therapeutics Inc. was incorporated in 2009 and is headquartered in Toronto, Canada. Antibe Therapeutics is traded on OTC Exchange in the United States.Things to note about Antibe Therapeutics performance evaluation
Checking the ongoing alerts about Antibe Therapeutics for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Antibe Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Antibe Therapeutics generated a negative expected return over the last 90 days | |
| Antibe Therapeutics has some characteristics of a very speculative penny stock | |
| Net Loss for the year was (25.06 M) with profit before overhead, payroll, taxes, and interest of 3.55 M. | |
| Antibe Therapeutics has accumulated about 50.19 M in cash with (16.92 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.96, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from thelincolnianonline.com: Timothy J. Arens Sells 7,009 Shares of Surmodics, Inc. Stock |
- Analyzing Antibe Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Antibe Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Antibe Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Antibe Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Antibe Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Antibe Therapeutics' pink sheet. These opinions can provide insight into Antibe Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Antibe Pink Sheet analysis
When running Antibe Therapeutics' price analysis, check to measure Antibe Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Antibe Therapeutics is operating at the current time. Most of Antibe Therapeutics' value examination focuses on studying past and present price action to predict the probability of Antibe Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Antibe Therapeutics' price. Additionally, you may evaluate how the addition of Antibe Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |